MOTS-c
Also known as: Mitochondrial Open Reading Frame of the 12S rRNA-c
MOTS-c is a catalog-expanded peptide entry in ProtoComp's source-backed compound corpus. It is included for search, calculator math, stack awareness, and future research curation based on expand compound catalog, local_seed. Published dosing, cycle length, and clinical-use claims are intentionally left null until compound-specific evidence is reviewed.
Mitochondrial-derived peptide. Limited human trials — dosing based on early clinical research.
Limited long-term human data. Off-cycles recommended until more research is available.
Off-cycle: 4 weeks
Early research suggests exercise-mimetic effects — morning dosing common.
Contraindications
- • Active mitochondrial disease
Common side effects
- • Injection site reactions
- • Fatigue (reported in early users)
Serious risks
- • Long-term safety unknown — limited human data
Requires monitoring
- • Fasting glucose
- • HbA1c if metabolic goals
Pregnancy / breastfeeding
No data — consult clinician
- Not a replacement for actual exercise — effects in humans are modest
Sign in to calculate your dose, add this compound to your stack, and check for interactions with your current cabinet.